TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis

“…Similarly, TP53 mutations were detected in only two cases (5%) compared with about 50% in advanced ovarian cancers. While most studies have reported similar low frequencies of 17p LOH and TP53 mutation in early stage ovarian tumours, Skomedal et al (1997) has reported p53 over expression and/or TP53 genetic mutations in a remarkable 50% of 347 stage I ovarian carcinomas. At least part of this high detection rate may be due to the more sensitive immunohistochemical and DNA mutation detection techniques used.…”

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

“…19,20,[23][24][25]28,29,39,42,46,[49][50][51]53,58,[61][62][63][64]66,[71][72][73][74][76][77][78][79]82,83,85,87,90,95,97,99,103,104,106,109,110,114 Overall, p53 was detected in 39% of the Stage I/II tumors and 55% of the Stage III/IV tumors ( Again, although antibody specific estimates by tumor grade varied considerably (data not shown), a consistent pattern emerged. Overall, the proportion of tumors positive for p53 was lowest among the Grade 1 tumors and highest among the Grade 3 tumors (Fig.…”

“…16,18,20,21,37,50,53,56,58 p53 was detected in 27 of 171 Stage I/II tumors (16%; 95% CI, 11-22%) and in 9 of 25 Stage III/IV tumors (36%; 95% CI, 18 -58%) (Fig. 4).…”

“…Similar to carcinomas, various definitions were used to classify the tumors of LMP as positive for p53. Few studies described their samples using specific percentages of positively stained tumor cells; however, 9 studies 16,21,31,37,40,45,48,58,59 provided information regarding the proportion of tumors that demonstrated staining in Ն 50% of the cells. In contrast to the carcinomas, for which the prevalence of p53 expression in Ն 50% of the cells was 29%, the prevalence among the tumors of LMP was only 5% (95% CI, 3-8%).…”

Role of p53 and Rb in Ovarian Cancer

“…Furthermore, a number of studies that have paid particular attention to histological criteria of malignancy of serous tumors have found that p53 mutations are strongly associated with high grade serous carcinomas, but are rare in low grade or borderline serous carcinomas (Kupryjanczyk et al, 1995;Kupryjanczyk et al, 1993;Skomedal et al, 1997;Zheng et al, 1995). In contrast, borderline/low grade tumors frequently harbor mutations in K-ras, which are very rare events in high grade serous adenocarcinomas (Cuatrecasas et al, 1997;Diebold et al, 2003;Singer et al, 2002;Singer et al, 2003a;Singer et al, 2003b;Zheng et al, 1995).…”